Granulocyte-macrophage colony stimulating factor: An adjuvant for cancer vaccines

77Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Granulocyte-macrophage colony stimulating factor (GM-CSF) enhances immune responses by inducing the proliferation, maturation, and migration of dendritic cells, and the expansion and differentiation of B and T lymphocytes. There is significant data in pre-clinical animal models demonstrating the adjuvant effects of GM-CSF in a variety of cancer vaccine approaches, including cellular vaccines, viral vaccines, peptide and protein vaccines, and DNA vaccines. GM-CSF is an attractive vaccine adjuvant because of its immune modulation effects and low toxicity profile. The results in animal models have been confirmed in pilot clinical trials and several clinical trials are currently ongoing. © 2004 Taylor & Francis Ltd.

Cite

CITATION STYLE

APA

Chang, D. Z., Lomazow, W., Somberg, C. J., Stan, R., & Perales, M. A. (2004). Granulocyte-macrophage colony stimulating factor: An adjuvant for cancer vaccines. Hematology, 9(3), 207–215. https://doi.org/10.1080/10245330410001701549

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free